

# QUARTERLY ACTIVITIES REPORT

**APPENDIX 4C -  
Quarter Ended 30 September 2022**

**19 October 2022**



## FORWARD-LOOKING STATEMENTS

### FORWARD-LOOKING STATEMENTS

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

## Continued Incremental Growth Ahead of Reimbursement

- **Growth in Core Business Metrics:**
  - Record results for Patient Tests, 47,000+ quarterly tests, +28% YOY
  - +34% YOY growth in Core SaaS fees
  - +38% in Average Monthly License Fees on US contract renewals
- **Focus on Corporate Accounts and IDNs**
  - Announced GenesisCare Global Strategic Commercial Partnership
  - Renewed or expanded agreements in 4 of 16 IDNs

## Reimbursement Traction

- CAP program delivering results that position us for coverage discussions
- Achieved interim coverage and pilot programs ahead of first policy determinations
- First coverage determinations expected in the current quarter
- NCCN outcomes expected to be known this quarter
- Sales strategy targeting areas of coverage

## Sound Financial Position, Focused on Cost Control

- Sound financial position, with \$34.9 million Cash on Hand
- 10+ quarters of operating cashflow<sup>^</sup>
- Measured cost control to align cash outflow with profitability targets
- Starting 2nd Half of FY'23, Net Operating Cash Outflow expected to be <\$(3.0) million per quarter<sup>^^</sup>

<sup>^</sup> Estimated quarters of funding available as calculated based on the Company's estimate of normalised, recurring cash flows.

The estimated quarters of funding available as calculated in note 8 of the Appendix 4C, Quarterly cash flow report is 6 quarters of funding, based on the temporary increase in spend in Q1 FY'23 for annual administrative costs and fees related to the change in management.

<sup>^^</sup> Based on an estimated foreign currency of \$1.00:\$0.66 AUD:USD. Continued foreign currency rates below this amount will have a positive impact on cash receipts and a negative impact on cash expenditures for reporting purposes.

## Q1 FY'23 OVERALL BUSINESS RESULTS

### TOTAL REVENUE

**\$2.9m**  
Q1 FY'23

✓ **RECORD QUARTER**

**+ 10%**  
YOY<sup>^</sup>

**\$2.7m**  
SOZO  
Business

✓ **RECORD QUARTER**

**+ 8%**  
YOY

- SaaS Revenue from Core Business
- SaaS Revenue from Clinical Business (AstraZeneca)
- New SOZO contracts signed and device revenue

**\$0.2m**  
Legacy  
Business

**\$2.9m**

**TOTAL Q1 REVENUE**

**+34%**

**CORE BUSINESS SAAS**

**\$34.9m**

**CASH ON HAND**

**10+ QUARTERS CASH  
AVAILABLE<sup>^^</sup>**

All FY'23 revenue and cash flow numbers are unaudited.  
All figures are stated in Australian dollars (AUD) unless otherwise notated.

<sup>^</sup> YOY denotes Year-over-Year change in metric.

<sup>^^</sup> Estimated quarters of funding available as calculated based on the Company's estimate of normalised, recurring cash flows.  
The estimated quarters of funding available as calculated in note 8 of the Appendix 4C, Quarterly cash flow report is 6 quarters of funding, based on the temporary increase in spend in Q1 FY'23 for annual administrative costs and fees related to the change in management.




Q1 FY'23 SOZO BUSINESS PERFORMANCE

Revenue and SaaS Metrics

- Incremental growth continues prior to full reimbursement
  - Record results for Total Revenue, SOZO Revenue and SOZO SaaS Revenue
- \$2.4m SOZO SaaS Revenue, +17% YOY and +5% QOQ
  - \$1.7m relates to the Core Business, +34% YOY
- \$9.2m ARR<sup>i</sup>, of which \$8.2m relates to the Core Business, +20% YOY
- \$19.1m CRP<sup>ii</sup>, +32% YOY; 90%+ SaaS Gross Margins on CRP
- \$4.1m TCV<sup>iii</sup> signed in Q1 FY'23
  - \$2.8m relates to the Core Business, +32% YOY
  - \$1.3m relates to the continued extension of an AstraZeneca clinical contract
- 1% Churn Rate & 94% customer Renewal Rate
- ~900 SOZO units sold in Core Business to date
  - 18 units sold in US in Q1 FY'23 - High quality accounts but below expectations
  - Pipeline in place to begin accelerating growth in Q2 FY'23

<sup>i</sup> Annual Recurring Revenue (ARR): The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.  
<sup>ii</sup> Contracted Revenue Pipeline (CRP): Future period revenue amounts related to TCV<sup>iii</sup> that are yet to be reported as recognised revenue.  
<sup>iii</sup> Total Contract Value (TCV): Total value of customer contracts including one-time and recurring revenue.

SOZO Revenue  
(Excluding Legacy)



<sup>^</sup>The values shown are for SaaS Revenue are across all lines of business, including the Core Business and Clinical Business.  
All FY'23 revenue and cash flow numbers are unaudited.  
All figures are stated in Australian dollars (AUD) unless otherwise notated.


## Q1 FY'23 SOZO BUSINESS PERFORMANCE

Strength of renewals and low churn helping to drive growth

- 38% Average Monthly License Fee increase across US renewal contracts
- This is up from the 34% increase achieved in Q4 FY'22
- Expectation for continued renewal increases for this financial year and into FY'24

Leveraging the power of our business model

- Stair step pricing model locks in growth before additional unit sales
  - Agreed price increases for years 2 and 3 for stair stepped contracts
  - ~\$2.7 million additional ARR over the next 12 months inherent in current SOZO contracts



**38%+ ↑**

Average Monthly License Fees on SOZO US renewals contracts in the period

**33%+ ↑**

Growth in ARR for 30 September 2023 before another SOZO unit sold

All FY'23 revenue and cash flow numbers are unaudited.  
All figures are stated in Australian dollars (AUD) unless otherwise notated.

^ YOY denotes Year-over-Year change in metric.

## FX IMPACTS AND CONSTANT CURRENCY ANALYSIS

Revenue positively impacted by dropping AUD:USD rate, but still growing when viewed in USD

- Q1 FY'23 was largest quarter of growth in USD when compared to prior two years
- +14% growth QOQ<sup>^</sup> in the Core Business license fee revenue in US, based on USD
- +25% growth YOY<sup>^^</sup>

### FX Impacts


- Total Revenue growth of 2% YOY on a constant currency basis, compared to the 10% reported based on AUD
- A continued drop in the AUD:USD foreign currency rate will have a positive impact on revenue and cash receipts and a negative impact on expenses
- The Company will continue to update the market on any relevant FX impacts on comparative numbers and percentages



All FY'23 revenue and cash flow numbers are unaudited.  
All figures are stated in Australian dollars (AUD) unless otherwise notated.

<sup>^</sup> QOQ denotes Quarter-over-Quarter change in metric.

<sup>^^</sup> YOY denotes Year-over-Year change in metric.



<sup>^</sup> Percentages in this graph signify the Quarter-over-Quarter change in metric.

Q1 FY'23 CASH FLOW

Sound Financial  
Position,  
Focused on  
Cost Control

Q1 FY'23  
\$34.9m  
CASH ON HAND



\$2.7m  
Cash Receipts from  
Customers

\$(5.7)m  
Total Net Operating  
Cash Outflow

\$(3.4)m - \$(3.6)m  
Recurring Net Operating  
Cash Outflow

Commentary:



Cash receipts continue  
to closely track Revenue

As outlined in prior 4C,  
Net Operating Cash  
Outflows temporarily  
increased in Q1 FY'23  
related to non-recurring  
or annual fees

Q2 FY'23 will contain  
some additional one-  
time fees related to  
measured cost controls^,  
but then will move below  
\$(3.0)M 2<sup>nd</sup> Half FY'23^^

STARTING 2ND HALF OF FY'23, TOTAL NET OPERATING CASH OUTFLOW  
EXPECTED TO BE BELOW \$(3.0) MILLION PER QUARTER

^ Q2 FY'23 will contain some additional one-time fees related to expenditure curtailment, but then expected to be below \$3.0 million per quarter in the second half of FY'23, with the ability to progress further below \$3.0 million as sales accelerate.  
^^ Based on an estimated foreign currency of \$1.00:\$0.66 AUD:USD. Continued foreign currency rates below this amount will have a positive impact on cash receipts and a negative impact on cash expenditures for reporting purposes.

All FY'23 revenue and cash flow numbers are unaudited.  
All figures are stated in Australian dollars (AUD) unless otherwise notated.



## FOCUS ON LARGE CORPORATE ACCOUNTS

High quality accounts signed or expanded, led by the addition of GenesisCare:

- Signed a Global Strategic Commercial Partnership and pilot program with Genesis Care:
  - Initial rollout of five (5) SOZO units to establish lymphoedema screening services for breast cancer patients
  - Scope within agreement to expand roll out globally upon successful completion of the pilot program
- Renewed or expanded agreements with Integrated Delivery Networks (IDNs) such as City of Hope, UPMC, Sutter Health, and Trinity Health
- Renewed or expanded agreements with NCCN Institutions such as City of Hope, Mayo Clinic, UT Southwestern, and Fred Hutchinson Cancer Center
- IDN, Corporate Account and NCCN Institution client base expanding:
  - In 16 of the Top 25 IDNs^
  - Agreements in place to allow rapid acceleration post reimbursement/coverage
  - Around a quarter of US SOZO devices are with IDNs or Corporate Accounts



Key IDNs, NCCN Institutions or Corporate Accounts added or extended in Q1 FY'23:



## RECORD PATIENT TESTING IN Q1 FY'23

Indicator of future health of business:

- Record results for Patient Tests conducted in the quarter, with 47,000+ tests conducted, +28% YOY
- 485,000+ Patient Tests now completed
- 500,000+ Patient Tests anticipated by the end of October^
- Latest 100,000+ Patient Tests achieved in just over six (6) months^



^Estimated based on a monthly run rate of 15,000+ Patient Tests and 485,000+ Patient Tests on file as of 30 September 2022.

# REIMBURSEMENT THE KEY - DUAL PATH APPROACH


## 1. Private Payor Reimbursement / Coverage

- Case Assistance Program (CAP) continuing to deliver results
- CAP produces the appeal wins needed to obtain coverage policies with health plans
- Strategy is focused on commercial coverage, initially through regional health plans
- Payor meetings have commenced
  - 3 of 10 initial Private Payor meetings have occurred
  - First 2 payor meetings successful based on initial payments
  - Third still in ongoing discussions
  - 4 additional meetings in November and 2 meetings in December
- Engaged in discussions with 4 regional health plans for commercial coverage policies
  - 2 Health Plans are now paying under a pilot program of coverage, prior to us obtaining commercial coverage
  - 2 additional Health Plans actively engaged in medical policy discussions for commercial coverage
- Focusing sales team resources in key areas that can leverage traction gained with regional health plans

## 2. NCCN Guidelines®

- NCCN Guidelines inclusion would establish BIS L-Dex as standard of care and significantly accelerate adoption by Private Payors and Providers
- The two independent submissions presented at the Annual Breast Cancer Panel meeting, held on 25 and 26 August, 2022, have been reviewed
- Additional independent submission to the NCCN Survivorship Panel for review at their annual Panel Meeting on 19 and 26 October, 2022, increasing the possibility of a positive outcome
- Expectation remains that any changes will be published by the end of the calendar year

## Path to obtaining Standard of Care





## CLINICAL UPDATE

Additional publications and data continue to expand the body of literature across all areas of the business

### 1. Lymphoedema Publications

- PREVENT Secondary Aims paper published in *Lymphatic Research and Biology*
- “A systematic literature review of the latest publications supporting screening and early intervention” published in *Journal of Cancer Survivorship*
- Expanded clinical body of evidence overwhelmingly supports BIS and is providing further evidence for Private Payor coverage submissions

### 2. Broader Oncology Publications

- Two independent papers studying the effects of sarcopenia detected by SOZO in breast cancer patients published:
  - Analysis of the impact of BIS-detected sarcopenia on chemotherapy-related toxicity in early-stage breast cancer patients and correlation to computed tomography (CT) scan published in *Breast Cancer*
  - Analysis of the impact of BIS-detected sarcopenia on endocrine therapy-related toxicity in early-stage breast cancer patients published in *Breast Cancer*

### 3. Heart Failure Presentations:

- Two posters presented at the 2022 Annual Heart Failure Society of America Meeting demonstrating the utility of the SOZO Digital Health Platform for Heart Failure Patients





## KEY MILESTONES: SUMMARY OF ACHIEVEMENTS IN Q1 FY'23

### CORP.

- ✓ Continued incremental growth in Revenue prior to full reimbursement, with a record result for Q1 FY'23, up 10% year-over-year to \$2.9 million.
- ✓ Record result in Q1 FY'23 for SOZO® SaaS Revenue, up 17% year-over-year to \$2.4 million.
- ✓ Record results for Patient Tests conducted in the quarter, with 47,000+ tests conducted, +28% YOY.

### ONCOLOGY

- ✓ Signed a Global Strategic Commercial Partnership with GenesisCare, with an initial rollout of five (5) sites.
- ✓ Expanded programs at top 25 Integrated Delivery Networks (IDN) and NCCN Institutions such as Mayo Clinic, City of Hope, UPMC, Sutter Health and Trinity Health.
- ✓ 38% Average Monthly License Fee increase across US renewals in the quarter.
- ✓ Case Assistance Program for reimbursement continues to deliver outstanding results.

### HF

- ✓ AdvocateAurora Health pilot program seeing strong data: (1) clinical experience demonstrates utility of SOZO with HF-Dex in tracking patient fluid volumes and (2) reimbursement available from coverage of CPT 93701 sufficient to more than cover the cost of delivering this service to patients.
- ✓ Two posters presented at the 2022 Annual Heart Failure Society of America Meeting demonstrating the utility of the SOZO Digital Health Platform for Heart Failure Patients.

### RENAL FAILURE

- ✓ Renal Observational Study has now closed for recruitment.
- ✓ Final patients completing protocol this month.
- ✓ Preliminary review of data looks promising.

## KEY MILESTONES: SUMMARY OF FOCUS AREAS FOR Q2 FY'23

### ONCOLOGY

- ☐ Advance private payor reimbursement coverage/payment for L-Dex® testing.
- ☐ Focus on accelerating sales while increasing average monthly license fees.
- ☐ Land and expand key cancer centres, medical oncology groups, IDNs and corporate accounts.

### HEART FAILURE

- ☐ Expand commercial sales of heart failure through additional pilot programs in key heart failure centres.
- ☐ Continue to progress SOZO II hardware development, with aim of removing the contraindications for implantable pacing and cardioverter defibrillator devices.

### RENAL FAILURE

- ☐ Renal Observational Study to be completed.
- ☐ Complete the data review and to discuss the outcomes with the principal investigators with a view to establishing next steps.
- ☐ Partner with the FDA and Principal Investigators in breakthrough sprint sessions on a clinical evidence plan and trial design for a renal failure interventional trial.

## Contact Details

### Investor Relations Contact:

Mike Bassett, ImpediMed

T : +61 407 431 432

E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

## About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO<sup>®</sup> for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).



19 October 2022

## ASX ANNOUNCEMENT

### QUARTERLY ACTIVITIES REPORT

#### APPENDIX 4C – Quarter Ended 30 September 2022 (Q1 FY'23)

ImpediMed Limited (ASX:IPD), today released its Appendix 4C – Quarterly Cash Flow report and Quarterly Activities Report for the period ended 30 September 2022.

#### Highlights:

- Record quarter for Total Revenue for Q1 FY'23 of \$2.9 million, +10% on the previous corresponding period (pcp).
- Record quarter for SOZO® Revenue for Q1 FY'23 of \$2.7 million, +8% pcp.
- Record quarter for SOZO SaaS Revenue for Q1 FY'23 of \$2.4 million, +17% pcp.
- \$4.1 million in Total Contract Value signed in Q1 FY'23, of which \$2.8 million relates to the Core Business, +32% pcp.
- Signed a Global Strategic Commercial Partnership and pilot program with Genesis Care.
  - Initial rollout of five (5) SOZO units to establish lymphoedema screening services for breast cancer patients.
  - Scope within agreement to expand roll out globally upon successful completion of the pilot program.

#### Revenue Summary:

- Record quarter for Total Revenue for Q1 FY'23 of \$2.9 million, +10% pcp (Q1 FY'22: \$2.6 million) and +3% quarter over quarter.
- Record quarter for SOZO Revenue for Q1 FY'23 of \$2.7 million, +8% pcp (Q1 FY'22: \$2.5 million) and +2% quarter over quarter.
- Record quarter for SOZO SaaS Revenue for Q1 FY'23 of \$2.4 million, +17% pcp (Q1 FY'22: \$2.1 million) and +5% quarter over quarter.
  - SOZO SaaS Revenue of \$1.7 million from Core Business<sup>i</sup>, +34% pcp.
  - SOZO SaaS Revenue of \$0.7 million from Clinical Business<sup>ii</sup>.

#### Cash Flow Summary:

- Cash on hand as at 30 September 2022 of \$34.9 million.
- Cash Receipts from Customers were \$2.7 million.
  - Cash receipts continue to strongly track Revenue.
- Net Operating Cash Outflows were \$(5.7) million.
  - As outlined in prior 4C, Net Operating Cash Outflows temporarily increased in Q1 FY'23 related to non-recurring or annual fees.
- Recurring Net Operating Cash Outflows in the range of \$(3.4) - \$(3.6) million.
  - Q2 FY'23 will contain some additional one-time fees related to measured cost controls, but then will move below \$(3.0) million per quarter for the 2<sup>nd</sup> Half FY'23.
- Related Parties: During the quarter, the Company Directors received a combination of cash remuneration, as well as issued shares as equity-based remuneration in lieu of cash, as described in Item 6 of the Appendix 4C.
- These payments to directors consisted of cash payments of \$59,000 as well as \$88,000 in Directors' fees accrued and unpaid at 30 September 2022 related to equity-based remuneration.



## **Operational Summary and Key SaaS Metrics:**

- Record results for Patient Tests conducted in the quarter, with 47,000+ tests conducted, +28% pcp.
- Annual Recurring Revenue<sup>iii</sup> of \$9.2 million, +20% pcp and +18% quarter over quarter.
  - ARR of \$8.2 million from Core Business, +20% pcp and +12% quarter over quarter.
  - ARR of \$1.0 million from Clinical Business.
- Contracted Revenue Pipeline<sup>iv</sup> of \$19.1 million, +32% pcp and +16% quarter over quarter.
- \$4.1 million in Total Contract Value (TCV<sup>v</sup>) signed in Q1 FY'23, of which \$2.8 million relates to the Core Business, +32% pcp.
- Over 90%+ Gross Margins on SaaS Revenue.
- Churn Rate remains negligible at just 1%.
  - 94% Renewal Rate on customers up for renewal during the period.
- ~900 SOZO units sold in Core Business to date.
  - 18 units sold in US in Q1 FY'23.
  - This was below expectations, but the quality of accounts signed remains extremely high.
  - Renewed or expanded agreements with Integrated Delivery Networks (IDNs) or NCCN Institutions such as City of Hope, UPMC, Sutter Health, and Trinity Health, Mayo Clinic, UT Southwestern, and Fred Hutchinson Cancer Center.

“We made good progress over the last quarter, and this quarter is shaping up to be pivotal to the future of ImpediMed. The key areas of focus are (1) advancing reimbursement, through Private Payor policy determinations and potentially NCCN Guidelines<sup>®</sup> inclusion; (2) revenue growth, focusing on both accelerating unit sales and further increasing the average monthly license fees; and (3) cost control. If we execute on these focus areas, then we will reach our goals of achieving profitability with the capital we have available,” stated David Anderson, Interim CEO and Director of ImpediMed.

**Approved for release by the Interim CEO and Director, Mr David Anderson.**

## **Contact Details**

### **Investor Relations Contact:**

Mike Bassett, ImpediMed

T : +61 407 431 432

E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

### **About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO<sup>®</sup> for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

## Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

---

<sup>i</sup> The **Core Business** refers to the commercialisation efforts from the Company's core strategic focus areas. To date, this primarily includes revenue from SOZO contracts in the Oncology market.

<sup>ii</sup> The **Clinical Business** refers to revenue generating contracts related to clinical trials. These contracts are often finite in nature, as they relate to clinical trials with specific end dates.

<sup>iii</sup> **Annual Recurring Revenue (ARR)**: The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.

<sup>iv</sup> **Contracted Revenue Pipeline (CRP)**: Future period revenue amounts related to TCV that are yet to be reported as recognised revenue.

<sup>v</sup> **Total Contract Value (TCV)**: Total value of customer contracts including one-time and recurring revenue.

- All FY'23 revenue and cash flow numbers are unaudited.
- CRP, ARR and TCV are non-IFRS financial metrics that do not represent revenue in accordance with Australian Accounting Standards.
- All figures are stated in Australian dollars (AUD) unless otherwise notated.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**
*ImpediMed Limited*
**ABN**

65 089 705 144

**Quarter ended ("current quarter")**

30 September 2022

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	2,743	2,743
1.2 Payments for		
(a) research and development	(319)	(319)
(b) product manufacturing and operating costs	(497)	(497)
(c) advertising and marketing	(277)	(277)
(d) leased assets	-	-
(e) staff costs	(6,241)	(6,241)
(f) administration and corporate costs	(2,908)	(2,908)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	114	114
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	1,667	1,667
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(5,718)</b>	<b>(5,718)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(6)	(6)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	(1,597)	(1,597)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(1,603)</b>	<b>(1,603)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(149)	(149)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	(100)	(100)
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>(249)</b>	<b>(249)</b>

Item 3.9: Cash inflows during the period relate to a temporary timing difference in relation to GST on capital raising costs, offset slightly by the recognition of costs under AASB 16 Leases for the Group's premises leases.

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	40,730	40,730
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(5,718)	(5,718)



Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1,603)	(1,603)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(249)	(249)
4.5	Effect of movement in exchange rates on cash held	1,724	1,724
4.6	<b>Cash and cash equivalents at end of period</b>	<b>34,884</b>	<b>34,884</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	8,923	9,444
5.2	Call deposits	25,961	31,286
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>34,884</b>	<b>40,730</b>

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	59
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Item 6.1: Payments to Directors consist of the portion Non-Executive Directors' fees paid as cash and superannuation. At 30 September 2022, there were \$88,000 in Directors' fees accrued and unpaid related to equity-based remuneration and superannuation.

<b>7.</b>	<b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	<b>Total financing facilities</b>	-	-
7.5	<b>Unused financing facilities available at quarter end</b>		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

<b>8.</b>	<b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1	Net cash from / (used in) operating activities (item 1.9)	(5,718)
8.2	Cash and cash equivalents at quarter end (item 4.6)	34,884
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	34,884
8.5	<b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	6
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer:	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer:	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer:	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

19 October 2022

Date: .....

Authorised by: Chair of Audit Committee & Interim CEO  
.....  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.